[1] |
World Health Organization . Global tuberculosis report 2017. Geneva: World Health Organization, 2017.
|
[2] |
任金凤, 赵跃, 王菊仙 . 抗结核药物研究新进展. 中国医药生物技术, 2016,11(4):360-364.
doi: 10.3969/j.issn.1673-713X.2016.04.014
URL
|
[3] |
胡水秀, 刘皇容 . 贝达喹啉治疗耐多药结核病的研究进展. 内科, 2017,12(4):508-512.
doi: 10.16121/j.cnki.cn45-1347/r.2017.04.19
URL
|
[4] |
赵嫄, 雷倩, 党丽云 , 等. 抗结核药物血药浓度监测工作的思考和展望. 中国防痨杂志, 2017,39(11):1228-1232.
|
[5] |
Choi R, Jeong BH, Koh WJ , et al. Recommendations for optimizing tuberculosis treatment:therapeutic drug monitoring,phamacogenetics, and nutritional status consderations. Ann Lab Med, 2017,37(2):97-107.
doi: 10.3343/alm.2017.37.2.97
URL
pmid: 28028995
|
[6] |
Alffenaar JW, Bolhuis M,van Hateren K,, et al.Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. Antimicrobial Agents Chemo-therapy, 2015,59(9):5675-5680.
doi: 10.1128/AAC.00276-15
URL
pmid: 4538542
|
[7] |
姚岚, 唐神结 . WHO 2014年版《耐药结核病规划管理指南伙伴手册》解读之四. 中国防痨杂志, 2015,37(5):534-536.
|
[8] |
高静韬, 刘宇红, 李亮 , 等. 从链霉素到贝达喹啉:抗结核药物临床试验发展70年历程回顾. 结核病与肺部健康杂志, 2016,5(1):14-18.
doi: 10.3969/j.issn.2095-3755.2016.01.006
URL
|
[9] |
中国防痨协会结核病临床专业委员会. 结核病临床诊治进展年度报告(2014年). 中国防痨杂志, 2015,37(7):673-721.
|
[10] |
王洪建, 冯连顺, 刘明亮 . 抗耐多药结核病新药的研发进展. 国外医药抗生素分册, 2017,38(5):193-200.
|
[11] |
Guglielmetti L, Le Dû D, Jachym M , et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis:interim analysis of a French cohort. Clin Infect Dis, 2015,60(2):188-194.
doi: 10.1093/cid/ciu786
URL
pmid: 25320286
|
[12] |
Guglielmetti L, Jaspard M, Le Dû D , et al.Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.Eur Respir J, 2017, 49(3): pii: 1601799.
doi: 10.1183/13993003.01799-2016
URL
pmid: 28182570
|
[13] |
Udwadia ZF, Ganatra S, Mullerpattan JB,. Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India . Eur Respir J , 2017,49(3): pii: 1601699.
doi: 10.1183/13993003.01699-2016
URL
pmid: 28331036
|
[14] |
Skrahina A, Hurevich H, Falzon D , et al. Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus ex-perience. Int J Mycobacteriol, 2016, Suppl 1: S62-63.
doi: 10.1016/j.ijmyco.2016.11.014
URL
pmid: 28043617
|
[15] |
Balcaen LI, De Samber B, De Wolf K , et al. Hyphenation of reverse-phase HPLC and ICP-MS for metabolite profiling-application to a novel antituberculosis compound as a case study. Anal Bioanal Chem, 2007,389(3):777-786.
doi: 10.1007/s00216-007-1303-2
URL
pmid: 17479254
|
[16] |
Cuyckens F, Balcaen LI, De Wolf K , et al. Use of the bromine isotope ratio in HPLC-ICP-MS and HPLC-ESI-MS analysis of a new drug in development. Anal Bioanal Chem, 2008,390(7):1717-1729.
doi: 10.1007/s00216-007-1761-6
URL
pmid: 18172622
|
[17] |
Meermann B, Bockx M, Laenen A , et al. Speciation analysis of bromine-containing drug metabolites in feces samples from a human in vivo study by means of HPLC/ICP-MS combined with on-line isotope dilution. Anal Bioanal Chem, 2012,402(1):439-448.
doi: 10.1007/s00216-011-5339-y
URL
pmid: 21877185
|
[18] |
Douša M, Reitmajer J, Lustig P , et al. Effect of chromatographic conditions on enantioseparation of bedaquiline using polysaccharide-based chiral stationary phases in RP-HPLC. J Chromatogr Sci, 2016,54(9):1501-1507.
doi: 10.1093/chromsci/bmw050
URL
pmid: 27071406
|